About Careers Internship MedBlog Contact us

Direct Dispensing of Naloxone to Reduce Opioid Overdose Deaths

by Ramya Rachamanti on May 8, 2019 at 10:35 AM
Direct Dispensing of Naloxone to Reduce Opioid Overdose Deaths

States that adopted laws which allow pharmacists to dispense opioid antidote naloxone directly, reduced the incidence of opioid overdose deaths by 27 percent during the second year and 34 percent in the following years, according to a new RAND Corporation study published in the journal JAMA Internal Medicine.

Researchers found that laws that encourage the distribution of naloxone -- but stop short of allowing direct dispensing by pharmacists -- did little to reduce opioid-related overdose deaths.


"This is strong evidence that greater use of naloxone can help reduce opioid-related deaths," said David Powell, a study co-author and a senior economist at RAND, a nonprofit research organization. "But how laws are structured to increase naloxone use is important. Weaker laws that do not give pharmacists direct dispensing authority did not curb opioid deaths."

While previous research has examined associations between expanded naloxone use and opioid-related deaths, the RAND study is the first to look at the impact of giving pharmacists direct authority to prescribe the drug.

The study also found that direct dispensing laws were associated with increased visits to hospital emergency departments for nonfatal opioid overdoses. Researchers say it was not clear if the increase was caused by fewer patients dying from opioid overdoses or whether other factors triggered an increase.

Overdose deaths from both prescription and recreational opioid use far exceed those from any prior U.S. drug epidemic. The number of opioid-related deaths each year since 2014 has surpassed the number of deaths associated with the peak of the HIV epidemic of the 1980s, as well as surpassing the number of deaths caused by auto accidents or gun violence.

Among the strategies adopted by state governments to combat the opioid crisis is increasing the distribution of naloxone, which can reverse the effects of an opioid overdose if given to a person promptly. In the case of an overdose, it usually is either injected or delivered as a nasal spray.

Most jurisdictions require naloxone to be dispensed only with a physician's prescription. Others have given pharmacists indirect authority to independently dispense the drug, such as allowing sales to people who meet certain criteria such as being enrolled in certain treatment programs. A growing number of states now allow naloxone to be sold directly to the public by pharmacists without a prescription.

The RAND study examined the policies across all states and the District of Columbia from 2005 to 2016, examining whether the adoption of different policies were associated with changes in opioid-related overdose deaths and the dispensing of naloxone.

While few states had naloxone access laws prior to 2010, rules encouraging dispensing of naloxone have grown quickly since then. By 2014, 15 states had laws that provide pharmacists with indirect authority to dispense naloxone. By 2016, nine states had laws allowing the direct dispensing of naloxone by pharmacists.

Researchers found that laws providing only indirect authority to pharmacists to dispense naloxone had little effect on increasing purchases of the drug. In contrast, states that adopted laws providing direct authority for pharmacists to dispense naloxone saw large increases in dispensing of the medication.

While stronger naloxone access laws significantly reduced deaths from opioid overdoses, the laws were not associated with fewer opioid overdoses overall. States with the direct dispensing laws saw an average 15 percent increase in nonfatal opioid-related emergency department visits relative to states that did not allow direct dispensing by pharmacists.

"These findings highlight the importance of coupling naloxone access laws with effective interventions and connections to treatment for patients seen in emergency departments for overdoses," said Rahi Abouk, the study's lead author and an economist at William Paterson University. "This is the location where such programs may be the most effective."

Source: Eurekalert
Font : A-A+



Recommended Readings

Latest Drug News

Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Direct Dispensing of Naloxone to Reduce Opioid Overdose Deaths Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests